ENLV logo

ENLIVEX LTD

ENLVNASDAQ
🏆 #5008 by market capEarnings Nov 12US Equity
$0.49▼ $0.03 (−5.83%)
After hours · at close
🔔
Track ENLV
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.8%
7d▼ 24.2%
14d▼ 46.3%
30d▼ 63.8%
ytd▼ 95.5%
1y▼ 96.8%
🏦Market Cap
$8M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$0.48 – $0.49
52-Week Range
$0.57 – $27.15
Volume
$2.13B
Avg Volume
$2.10B
Shares Outstanding
16.8M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$390,832
P/E Ratio
0.0
P/S Ratio
0.0x
EPS (TTM)
$212.35
Dividend Yield
0.00%
Dilution (1yr)
+120.1%

Why Investors Own ENLV

  • ✓High-growth profile — revenue up +2.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 64% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ENLV logo

ENLIVEX LTD

ENLV
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$15M▼ −3.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$10M▼ −20.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.2M▲ +120.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1M▼ −$1M YoY
StockOtter · stockotter.space

About ENLIVEX LTD

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$0.62
▲ +26.4% Upside
High Target$0.76
Low Target$0.47
Based on 21 analysts

Latest News & Updates

🚀
Reuters·2h ago

ENLIVEX LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift ENLV price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

ENLIVEX LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.